Quarterly report pursuant to Section 13 or 15(d)

NON-CONTROLLING INTEREST (Details) - Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net

v3.20.2
NON-CONTROLLING INTEREST (Details) - Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net - Noncontrolling Interest [Member] - USD ($)
3 Months Ended 9 Months Ended
Sep. 30, 2019
Sep. 30, 2020
Sep. 30, 2019
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]      
Balance   $ 514,828  
Allocation of equity to non-controlling interest due to equity-based compensation issued   2,636,298  
Allocation of equity to non-controlling interest due to sale of common stock   3,467,709  
Allocation of equity to non-controlling interest due to issuance of equity to acquire Trek and research and development $ 426,212 3,467,709 $ 426,212
Net loss attributable to non-controlling interest   (6,282,420)  
Balance   1,320,312  
Trek Therapeutics [Member]      
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]      
Allocation of equity to non-controlling interest due to issuance of equity to acquire Trek and research and development   $ 983,897